Melanoma Clinical Trial
A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Summary
The purpose of this study is to evaluate two different dose combinations of nivolumab and ipilimumab in the treatment of melanoma.
Eligibility Criteria
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria:
Subject must have been diagnosed with stage III or/and stage IV histologically confirmed melanoma [per American Joint Committee on Cancer (AJCC) staging system] that is unresectable or metastatic
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
Subject has not been treated by systemic anticancer therapy for unresectable or metastatic melanoma
Exclusion Criteria:
Subjects with active brain metastases or leptomeningeal metastases
Subjects with ocular melanoma
Subjects with active, known or suspected autoimmune disease
Other protocol defined inclusion/exclusion criteria could apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 57 Locations for this study
Aurora Colorado, 80045, United States
Tampa Florida, 33612, United States
Fridley Minnesota, 55432, United States
Saint Louis Missouri, 63110, United States
Las Vegas Nevada, 89148, United States
Lebanon New Hampshire, 03756, United States
Hackensack New Jersey, 07601, United States
Charlotte North Carolina, 28204, United States
Allentown Pennsylvania, 18103, United States
Charlottesville Virginia, 22908, United States
Seattle Washington, 98109, United States
North Sydney New South Wales, 2060, Australia
Waratah New South Wales, 2298, Australia
Greenslopes Queensland, 4120, Australia
Melbourne Victoria, 3004, Australia
Edmonton Alberta, T6G 1, Canada
Toronto Ontario, M5G 2, Canada
Quebec , G1R 2, Canada
Aarhus N , 8200, Denmark
Herlev , 2730, Denmark
Odense , 5000, Denmark
Bordeaux , 33075, France
Lille , 59037, France
Marseille Cedex 5 , 13385, France
Nantes Cedex , 44093, France
Paris , 75475, France
Pierre Benite , 69310, France
Toulouse Cedex 9 , 31059, France
Villejuif , 94805, France
Essen , 45147, Germany
Heidelberg , 69120, Germany
Muenchen , 80337, Germany
Tuebingen , 72076, Germany
Ramat Gan , 52621, Israel
Bergamo , 24127, Italy
Milano , 20133, Italy
Napoli , 80131, Italy
Padova , 35128, Italy
Siena , 53100, Italy
Taormina , 98039, Italy
Amsterdam , 1066 , Netherlands
Amsterdam , 1081 , Netherlands
Groningen , 9700R, Netherlands
Gdansk , 80-21, Poland
Krakow , 31-11, Poland
Warszawa , 02-78, Poland
Moscow , 11547, Russian Federation
Badalona-barcelona , 08916, Spain
Barcelona , 08036, Spain
Madrid , 28007, Spain
Madrid , 28034, Spain
San Sabastian Gipuzkoa , 20014, Spain
Valencia , 46014, Spain
Manchester Greater Manchester, M20 4, United Kingdom
Oxford Oxfordshire, OX3 7, United Kingdom
Guildford , GU2 7, United Kingdom
London , SW3 6, United Kingdom
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.